Andere talen Invites Biocore Co., Ltd.

Aandelen

A216400

KR7216400002

slotkoers Korea S.E. Andere beurzen 00:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7.180 ^KRW	+6,37%		-0,97%	-22,80%

2022

Invites Biocore Co., Ltd. (XKON:A216400) de overname van 85% belang in PROCAGEN van Byun Seok-soo af.

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion	28/12
Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion	17-05-23
Invites Biocore Co., Ltd. completed the acquisition of 85% stake in PROCAGEN from Byun Seok-soo.	15-07-22
Invites Biocore Co., Ltd. agreed to acquire 85% stake in PROCAGEN from Byun Seok-soo.	14-07-22
Biocore Co., Ltd. announced that it has received KRW 41.999997 billion in funding	31-03-21
Biocore Co., Ltd. announced that it expects to receive KRW 41.999997 billion in funding	17-02-21
BioCore Inc. Signs Agreement with Osprey Medical, Inc	25-11-20
Biocore Co., Ltd. announced that it has received KRW 7.99999527 billion in funding	08-07-20
Invites Healthcare Co., Ltd. agreed to acquire a 20.03% stake in Biocore Co., Ltd. from Hongkong Dian Biotechnology Co., Limited for KRW 12 billion.	01-07-20
Biocore Co., Ltd. announced that it expects to receive KRW 7.99999527 billion in funding	30-06-20
Biocore Co., Ltd. announced that it expects to receive KRW 5.04114275 billion in funding	01-10-19
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion.	02-08-16
Kiwoom Securities Co., Ltd. acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion.	02-08-16
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd., MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion.	02-08-16
SBI Investment Korea Co., Ltd. through its SBI-Growth Ladder KONEX Vitalization Fund acquired 2.3% stake in Biocore Co., Ltd. from Kyungryul Lee for KRW 1.9 billion.	29-07-16
Moon-Kyu Gong acquired 1.22% stake in Biocore Co., Ltd. from Jeong-Woo Lee for KRW 700 million.	27-10-15
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion.	27-10-15
Biocore Co., Ltd. completed the acquisition of Cytogenetic and Human Genome division of Seoul Clinical Laboratories.	21-10-15
Biocore Co., Ltd. agreed to acquire Cytogenetic and Human Genome division of Seoul Clinical Laboratories for KRW 2.9 billion.	18-08-15
Intelsius Announces Partnership with Biocore Co. Ltd. in South Korea	27-03-12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Invites Biocore Co., Ltd.

Aandelen

A216400

KR7216400002

Andere talen

Filters